BeOne Medicines Guangzhou

BeOne Medicines Guangzhou Ltd. is a global, commercial-stage, research-based biotechnology company focused on the development of molecularly targeted and immuno-oncology therapies. It is the world's first biopharmaceutical enterprise to be listed on the "A+H+N" three exchanges simultaneously, earning a place in the top ten of the 2022 Pharmaceutical Innovation Index and Pharmaceutical Invention Index, as well as ranking among the top ten global pharmaceutical companies. It has repeatedly topped the list for R&D expenditure among Chinese pharmaceutical companies and ranks first among China's biopharmaceutical enterprises.